Anti-TNF-α therapy can also shift the immune system to Th-2, upregulating the production of antibodies, including anti-nuclear, anti-dsDNA, and anti-neutrophil cytoplasmic antibodies, which may lead to the development of lupus-like and/or crescentic glomerulonephritis in susceptible individuals. Here, TNF is linked to systemic lupus erythematosus.